EP0684838A1 - Compositions de vaccin contre la grippe, contenant un lipide a de monophosphoryle desacyle en position 3-o - Google Patents

Compositions de vaccin contre la grippe, contenant un lipide a de monophosphoryle desacyle en position 3-o

Info

Publication number
EP0684838A1
EP0684838A1 EP94908327A EP94908327A EP0684838A1 EP 0684838 A1 EP0684838 A1 EP 0684838A1 EP 94908327 A EP94908327 A EP 94908327A EP 94908327 A EP94908327 A EP 94908327A EP 0684838 A1 EP0684838 A1 EP 0684838A1
Authority
EP
European Patent Office
Prior art keywords
mpl
vaccine composition
composition according
protein
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94908327A
Other languages
German (de)
English (en)
Inventor
Susan Dillon
Hirotoshi Nishikawa
Paul Dal Monte
Robert J. Gyurick
Nathalie Marie-Josephe Claude Garcon-Johnson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Biologicals SA
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Biologicals SA, SmithKline Beecham Corp filed Critical SmithKline Beecham Biologicals SA
Publication of EP0684838A1 publication Critical patent/EP0684838A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention se rapporte à des compositions de vaccins susceptibles de renforcer une réaction protectrice par rapport à un antigène de la grippe choisi, la composition contenant au moins cet antigène et le lipide A de monophosphoryle désacylé en position 3-O (3D-MPL). Des procédés de renforcement de la réponse immunitaire à la grippe à l'aide de ces compositions sont également décrits.
EP94908327A 1993-02-19 1994-02-15 Compositions de vaccin contre la grippe, contenant un lipide a de monophosphoryle desacyle en position 3-o Withdrawn EP0684838A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2153593A 1993-02-19 1993-02-19
US21535 1993-02-19
US11575093A 1993-09-01 1993-09-01
US115570 1993-09-01
PCT/EP1994/000448 WO1994019013A1 (fr) 1993-02-19 1994-02-15 Compositions de vaccin contre la grippe, contenant un lipide a de monophosphoryle desacyle en position 3-o

Publications (1)

Publication Number Publication Date
EP0684838A1 true EP0684838A1 (fr) 1995-12-06

Family

ID=26694802

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94908327A Withdrawn EP0684838A1 (fr) 1993-02-19 1994-02-15 Compositions de vaccin contre la grippe, contenant un lipide a de monophosphoryle desacyle en position 3-o

Country Status (9)

Country Link
EP (1) EP0684838A1 (fr)
AP (1) AP431A (fr)
AU (1) AU6141094A (fr)
CA (1) CA2156525A1 (fr)
IL (1) IL108681A0 (fr)
MA (1) MA23118A1 (fr)
MX (1) MX9401225A (fr)
SI (1) SI9400085A (fr)
WO (1) WO1994019013A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
DE69405551T3 (de) * 1993-03-23 2005-10-20 Smithkline Beecham Biologicals S.A. 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6306404B1 (en) 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
GB9820525D0 (en) * 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
US6261573B1 (en) * 1998-10-30 2001-07-17 Avant Immunotherapeutics, Inc. Immunoadjuvants
AT407958B (de) * 1999-02-11 2001-07-25 Immuno Ag Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
US6635261B2 (en) 1999-07-13 2003-10-21 Wyeth Holdings Corporation Adjuvant and vaccine compositions containing monophosphoryl lipid A
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
AR032575A1 (es) * 2001-02-23 2003-11-12 Smithkline Beecham Biolog Uso de una preparacion antigenica de gripe para la fabricacion de una vacuna intradermica de la gripe y estuche farmaceutico que comprende dicha vacuna
DE60239594D1 (de) * 2001-02-23 2011-05-12 Glaxosmithkline Biolog Sa Influenza vakzinzusammensetzungen zur intradermaler verabreichung
EP1381344A4 (fr) * 2001-04-27 2008-06-11 Glaxosmithkline Biolog Sa Nouveau vaccin
CA2890962A1 (fr) 2004-09-09 2006-03-16 Novartis Vaccines And Diagnostics Gmbh & Co. Kg Reduction de risques iatrogenes potentiels associes aux vaccins contre la grippe
AU2005314563B2 (en) 2004-11-03 2011-06-30 Seqirus UK Limited Influenza vaccination
PE20061428A1 (es) 2005-03-23 2007-01-16 Glaxosmithkline Biolog Sa Formulacion de vacuna que comprende un adyuvante de emulsion aceite en agua y 3d-mpl
MX2009000660A (es) 2006-07-17 2009-04-08 Glaxosmithkline Biolog Sa Vacuna de influenza.
WO2008134830A1 (fr) * 2007-03-22 2008-11-13 Fundação Butantan Procédé pour obtenir le lipide monophosphorylé a à partir de bordetella pertussis comme sous-produit de la production du vaccin cellulaire anti-coquelucheux
US9452209B2 (en) 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
JP5518041B2 (ja) * 2008-03-18 2014-06-11 ノバルティス アーゲー インフルエンザウイルスワクチン抗原の調製における改良
AU2011300402B2 (en) 2010-09-07 2015-01-22 Novartis Ag Generic assays for detection of mammalian reovirus
CN106535929A (zh) * 2014-03-25 2017-03-22 美国政府陆军部 增强铝盐吸附疫苗的免疫刺激效力的方法
WO2020010394A1 (fr) * 2018-07-10 2020-01-16 Seqirus Pty Ltd Élimination d'agglomérats
CN112361796A (zh) * 2020-11-13 2021-02-12 安徽省天长市周氏羊业有限公司 一种秸秆回收储存前破碎干燥装置
CN114989269B (zh) * 2022-06-30 2023-09-19 天康制药股份有限公司 一种牛赤羽免疫原性抗原及疫苗

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5230899A (en) * 1985-08-07 1993-07-27 Smithkline Beecham Corporation Methods and compositions for making liposomes
IL79114A (en) * 1985-08-07 1990-09-17 Allergan Pharma Method and composition for making liposomes
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
AU631377B2 (en) * 1988-08-25 1992-11-26 Liposome Company, Inc., The Affinity associated vaccine
AU640348B2 (en) * 1988-08-31 1993-08-26 Smithkline Beecham Corporation Vaccinal Polypeptides
DK425789A (da) * 1988-08-31 1990-03-01 Smithkline Beecham Corp Vaccinale polypeptider
KR100194079B1 (ko) * 1990-09-28 1999-06-15 장 스테판느 Hiv 감염 예방 또는 치료용 제약학적 조성물 및 이의 제조방법
WO1992011291A1 (fr) * 1990-12-20 1992-07-09 Smithkline Beecham Biologicals (S.A.) VACCINS A BASE DE l'ANTIGENE D'ENVELOPPE DU VIRUS DE L'HEPATITE B
FR2671974A1 (fr) * 1991-01-24 1992-07-31 Pasteur Merieux Serums Vacc Composition vaccinale contre la grippe, a effet synergique, contenant comme additif du core de virus grippal.
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
HU219808B (hu) * 1992-06-25 2001-08-28 Smithkline Beecham Biologicals S.A. Adjuvánst tartalmazó vakcinakompozíció és eljárás annak előállítására

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9419013A1 *

Also Published As

Publication number Publication date
AU6141094A (en) 1994-09-14
IL108681A0 (en) 1994-05-30
SI9400085A (en) 1994-09-30
WO1994019013A1 (fr) 1994-09-01
AP431A (en) 1995-11-15
MX9401225A (es) 1994-08-31
AP9400621A0 (en) 1994-04-30
CA2156525A1 (fr) 1994-09-01
MA23118A1 (fr) 1994-10-01

Similar Documents

Publication Publication Date Title
AP431A (en) Influenza vaccine compositions.
JP6062245B2 (ja) 組換えｒｓｖ抗原
JP5775451B2 (ja) インフルエンザを処置するための組成物および方法
US20130089570A1 (en) Oral vaccine compromising an antigen and a toll-like receptor agonist
ES2678694T3 (es) Vacuna
JP6119030B2 (ja) インフルエンザを治療するための組成物及び方法
EP3154576A1 (fr) Combinaisons immunogènes
MXPA02003068A (es) Adyuvante que comprende un eter o ester alquilo de polioxietileno y al menos un tensioactivo no ionico..
JP4685005B2 (ja) アジュバントを含む機能的に再構成されたウイルス膜
CA2169297C (fr) Vaccins a base de cochleate proteique ou peptidique et procedes d'immunisation faisant appel a ces vaccins
EP2058002A1 (fr) Membranes reconstituées du virus respiratoire syncytial et utilisation en tant que vaccin contre le virus respiratoire syncytial
JP2018172417A (ja) 乳児においてｒｓｖ及び百日咳菌に対する免疫応答を惹起するための方法
JPH08506592A (ja) ３−ｏ−脱アシル化モノホスホリル脂質Ａ含有のインフルエンザワクチン組成物
WO2012006368A2 (fr) Compositions et méthodes pour traiter la grippe
JP2015525794A (ja) 乳児においてｒｓｖ及び百日咳菌に対する免疫応答を惹起するための方法
US20050152919A1 (en) Measles subunit vaccine
AU2007228736B2 (en) Intranasal influenza vaccine based on virosomes
Fujii et al. The VesiVax system: a method for rapid vaccine development
MX2013003451A (es) Generacion de particulas de virosoma.
WO2020067302A1 (fr) Adjuvant muqueux
US20160151479A1 (en) Method for preparing virosomes
JP2021506911A (ja) ヘンドラウイルス感染症及びニパウイルス感染症に対するワクチン
WO1997041891A1 (fr) Compositions et procedes de protection contre des isolats du virus de la grippe immunologiquement differents

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950731

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19980901